NAFLD Management
On this page
Direct answer
Steatosis on ultrasound in someone drinking little or no alcohol — nowadays termed metabolic dysfunction-associated steatotic liver disease (MASLD), formerly NAFLD — has become the commonest chronic liver disease in India, where urban prevalence estimates run to roughly a quarter or more of adults, driven by diabetes, obesity and sedentary transition. The single task that changes management is fibrosis staging, because simple steatosis is benign while steatohepatitis (MASH) with significant fibrosis drives cirrhosis and hepatocellular carcinoma risk; FIB-4 under 1.3 is reassuring, above 2.67 predicts advanced fibrosis, and the middle band goes to elastography (8 kPa or more suggests significant fibrosis). Therapy remains anchored on 7-10 percent weight loss — which can resolve steatohepatitis and even regress fibrosis at 10 percent — supported by pioglitazone 30-45 mg or vitamin E 800 IU daily in selected non-diabetic biopsy-proven MASH, with resmetirom (the first approved MASH drug, March 2024) for non-cirrhotic F2-F3 disease.
What you must remember
- Nomenclature update to quote: NAFLD has been redefined as MASLD (metabolic dysfunction-associated steatotic liver disease) from 2023, requiring steatosis plus at least one cardiometabolic criterion (BMI/waist, prediabetes or diabetes, hypertension, hypertriglyceridaemia, low HDL); steatohepatitis becomes MASH.
- The staging gate: FIB-4 (age, AST, ALT, platelets) — under 1.3 low risk (1.3-2.67 needs elastography; over 2.67 high risk); transient elastography 8 kPa or more suggests significant fibrosis (F2+), around 12-15 kPa or a compatible picture suggests cirrhosis.
- Weight loss dose-response: 5 percent improves steatosis, 7 percent resolves steatohepatitis in many, 10 percent can regress fibrosis — the numbers the exam asks by name.
- Pharmacotherapy specifics: pioglitazone 30-45 mg daily (best in biopsy-proven MASH with or without type 2 diabetes, weight gain and heart failure caution); vitamin E 800 IU/day (non-diabetic, non-cirrhotic biopsy-proven MASH; haemorrhagic stroke and prostate cancer signals discussed); resmetirom 80-100 mg daily — THR-beta agonist, accelerated FDA approval March 2024 for non-cirrhotic MASH with F2-F3 fibrosis.
- Drugs that are not the answer: UDCA is ineffective; statins are safe in NAFLD/MASLD and indicated for the dyslipidaemia — a favourite trick question.
- Comorbidity is the prognosis: cardiovascular disease is the leading cause of death in MASLD ahead of liver disease, so diabetes control, blood pressure, lipids and smoking cessation are management, not an afterthought.
- Lean MASLD: a substantial Indian minority (often quoted around a tenth to a fifth of cases) is non-obese, with sarcopenia and metabolic dysfunction despite normal BMI — the "lean fatty liver" of South Asian phenotype, driven by body composition rather than weight.
- Follow-up discipline: cirrhosis-stage patients enter variceal and hepatocellular carcinoma surveillance (ultrasound every six months); F0-F2 patients re-stage every two to three years with FIB-4 or elastography.
Fibrosis staging: the real decision
A 46-year-old man with type 2 diabetes and a BMI of 29 is referred for ultrasound-reported fatty liver; AST 62, ALT 78, platelets 210,000. FIB-4 calculates to 0.98 — low risk — so he needs no hepatology referral; his management is cardiometabolic: 8 percent weight-loss target through diet and structured exercise, glycaemic optimisation preferring agents with weight benefit (semaglutide or tirzepatide where appropriate, though their liver indications remain under study), and statin therapy for his dyslipidaemia. Contrast a 58-year-old diabetic woman with platelets of 132,000 and AST 85: her FIB-4 of 2.9 demands elastography, which reads 11.8 kPa — significant-to-advanced fibrosis; a MASH-F3 picture puts resmetirom, pioglitazone, and rigorous weight intervention on the table, plus screening for portal hypertension, because her liver-related mortality risk is an order of magnitude above the first patient's.
The decision tree is therefore not "how fatty is the liver" but "how stiff" — every branch of management flows from that number.
How the question is framed
NEET-PG stems hide the staging question inside laboratory values: the candidate is handed age, AST, ALT and platelets and expected to compute or estimate FIB-4 and choose referral versus reassurance. The second recurring frame is the vitamin E question — 800 IU daily in non-diabetic, non-cirrhotic biopsy-proven MASH — with wrong options including UDCA, metformin and "no treatment exists"; resmetirom's 2024 approval now belongs in that answer list for F2-F3 disease. Indian papers also exploit the lean-MASLD paradox: a normal-BMI vegetarian with diabetes and fatty liver is not a contradiction but a South Asian phenotype question. Finally, remember the mortality order — cardiovascular first, extrahepatic malignancy second, liver third — which makes the "best initial intervention" in many stems the statin or the lifestyle prescription, not a liver drug.
Frequently asked questions
How is NAFLD/MASLD staged non-invasively?
FIB-4 first (under 1.3 low risk, above 2.67 high risk), with transient elastography for the indeterminate band — 8 kPa or more suggesting significant fibrosis — reserving biopsy for discordant or uncertain cases.
What degree of weight loss improves liver histology?
Around 5 percent improves steatosis, 7 percent can resolve steatohepatitis, and 10 percent is associated with fibrosis regression — making structured weight loss the cornerstone of therapy.
Which drugs are used for biopsy-proven MASH?
Pioglitazone 30-45 mg daily, vitamin E 800 IU daily in non-diabetic non-cirrhotic patients, and resmetirom 80-100 mg daily — the first FDA-approved MASH drug (March 2024) for non-cirrhotic F2-F3 fibrosis.
What is lean MASLD?
Steatotic liver disease with metabolic dysfunction in non-obese individuals — common in the South Asian phenotype where body fat distribution and sarcopenia, not BMI, drive insulin resistance.
What is the leading cause of death in MASLD?
Cardiovascular disease, ahead of extrahepatic malignancy and liver-related death — so risk-factor control is central to management regardless of liver stage.